The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACON | -99.59% | N/A | N/A | -100% |
| S&P | +13.22% | +85.17% | +13.11% | +60% |
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.
No news articles found for Aclarion.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.02M | 31.5% |
| Gross Profit | -$0.05M | 5.2% |
| Gross Margin | -284.96% | 110.4% |
| Market Cap | $4.37M | 137.1% |
| Market Cap / Employee | $0.73M | 0.0% |
| Employees | 6 | 50.0% |
| Net Income | -$1.71M | -24.9% |
| EBITDA | -$1.77M | -42.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.37M | 759.7% |
| Accounts Receivable | $0.03M | 88.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -89.50% | 175.5% |
| Return On Invested Capital | -42.39% | -191.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.17M | -41.9% |
| Operating Free Cash Flow | -$1.16M | -41.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.84 | 0.00 | 0.28 | 0.31 | -58.07% |
| Price to Sales | 36.54 | 43.39 | 69.62 | 64.72 | 84.30% |
| Price to Tangible Book Value | 10724.29 | 0.01 | 0.30 | 0.34 | -100.00% |
| Enterprise Value to EBITDA | -0.69 | 8.62 | 5.03 | 3.95 | -1303.31% |
| Return on Equity | -5777.8% | -72.5% | -88.4% | -97.7% | -86.89% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
